(Q37599318)

21 August 2017

1 reference

title

The Diabetes Control and Complications Trial: the gift that keeps giving (English)

1 reference

21 August 2017

Stephen L Atkin

3

0 references

author name string

Eric S Kilpatrick

series ordinal

1

1 reference

PubMed ID

19763126

21 August 2017

Alan S Rigby

series ordinal

2

1 reference

21 August 2017

1 October 2009

1 reference

Nature Reviews Endocrinology

21 August 2017

1 reference

21 August 2017

5

1 reference

21 August 2017

10

1 reference

21 August 2017

537-545

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2009.179

21 August 2017

0 references

cites work

The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Postprandial hyperglycemia and diabetes complications: is it time to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and preproliferative retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Normoglycaemic Re-entry and Diabetic Complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

10-year follow-up of intensive glucose control in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Should minimal blood glucose variability become the gold standard of glycemic control?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

The effect of glucose variability on the risk of microvascular complications in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

The pathobiology of diabetic complications: a unifying mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT S

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complicat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Translating the A1C assay into estimated average glucose values

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

The IFCC Reference Measurement System for HbA1c: a 6-year progress report.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.179

The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial

31 March 2020

1 reference

12 December 2020

Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group

1 reference

12 December 2020

The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group

1 reference

12 December 2020

Glycated hemoglobin: methodologies and clinical applications

1 reference

12 December 2020

The national glycohemoglobin standardization program: a five-year progress report.

1 reference

12 December 2020

Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial

1 reference

12 December 2020

Long-term effect of diabetes and its treatment on cognitive function.

1 reference

12 December 2020

Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study

1 reference

12 December 2020

The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial

1 reference

12 December 2020

Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group

1 reference

12 December 2020

The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.179

1 reference

21 August 2017

1 reference

PubMed ID

19763126